Nov 19 2008
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of its Invivofectamine(TM) delivery reagent which enables short interference ribonucleic acid (siRNA) experiments in vivo.
The study of RNA interference (RNAi) has revolutionized biology by allowing researchers to directly observe the effects of the loss of function of specific genes in mammalian systems. Using proprietary technology, the Invivofectamine™ delivery reagent allows researchers to directly study the effects of siRNA inside a living organism for a variety of applications, including the drug discovery process.
“The Invivofectamine™ reagent is a major breakthrough for the development of RNAi applications in animals that could lead to the rapid discovery of new therapeutic solutions for diseases such as cancer and metabolic diseases,” said Charles Piazza, Vice President and General Manager of Invitrogen’s Molecular Biology. “Invivofectamine™ reagent gives customers the ability to perform in vivo RNAi experiments that have so far been difficult to perform due to the lack of an effective and easy-to-use delivery reagent.”
As opposed to current offerings on the market, Invivofectamine™ delivery reagent can be injected in small volumes and without high pressure, minimizing the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.
For more information, visit www.invitrogen.com/invivornai.